葛兰素史克Glaxosmithkline（GSK）2025年第三季度财报「LSE」（英文版）（56页）.pdf

1、GSK delivers strong Q3 performance and upgrades 2025 guidanceSpecialty Medicines,Vaccines and General Medicines drive sales,profit and earnings growthTotal Q3 2025 sales 8.5 billion+7%AER;+8%CERSpecialty Medicines sales 3.4 billion(+16%);Respiratory,Immunology&Inflammation 1.0 billion(+15%);Oncology

2、 0.5 billion(+39%);HIV sales 1.9 billion(+12%)Vaccines sales 2.7 billion(+2%);Shingrix 0.8 billion(+13%);Meningitis vaccines 0.5 billion(+5%);and Arexvy 0.3 billion(+36%)General Medicines sales 2.5 billion(+4%);Trelegy 0.7 billion(+25%)Total operating profit 100%and Total EPS 100%driven by lower Sig

3、nificant legal expenses,lower CCL charges and higher other operating income,partly offset by intangible asset impairmentsCore operating profit+11%and Core EPS+14%reflecting Specialty Medicines and Vaccines growth,higher royalty income and disciplined increased investment in R&D portfolio progression

4、 in Oncology and VaccinesCash generated from operations of 2.5 billion with free cash flow of 1.2 billion(Financial Performance Q3 2025 results unless otherwise stated,growth%and commentary at CER as defined on page 50.In Q3 2025 and YTD 2025,the adverse currency impact on AER versus CER primarily r

5、eflected the strengthening of Sterling against the USD.See page 11 for further details.)Q3 2025Year to datem%AER%CERm%AER%CERTurnover 8,547 7 8 24,049 3 6 Total operating profit 2,593 100100 6,832 100100Total operating margin%30.3%28.0ppts 28.5ppts 28.4%14.1ppts 14.5ppts Total EPS 49.9p 100100 125.1

6、p 100100Core operating profit 2,985 8 11 8,149 6 9 Core operating margin%34.9%0.4ppts 0.9ppts 33.9%0.7ppts 1.0ppts Core EPS 55.0p 11 14 146.3p 7 11 Cash generated from operations 2,520 1 6,254 19 Pipeline progress and investment delivering future growth opportunities:4 major new product approvals ac